Karen leads Epitopea’s Vaccine Technology team, driving the design and optimisation of RNA-based cancer immunotherapies, including the establishment of the company’s RNA vaccine pipeline from the ground up.

This platform has enabled the accelerated progression of Epitopea’s first cancer vaccine candidate towards the clinic. She brings over 10 years of hands-on experience in RNA biology and vaccine development, with prior roles at VaxEquity and Imperial College London, where she developed high throughput cloning strategies, optimised large-scale in vitro transcription and QC of RNA vaccines.

She is driven by a passion to translate cutting-edge science to advance the delivery of impactful therapeutic solutions that improve patient outcomes.